Boothbay Fund Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Boothbay Fund Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-46,437	Closed	-$571K	–	2278
2023 Q2	$571K	Sell	46,437 -70,999	-60%	-$888K	0.01%	1037
2023 Q1	$1.44M	Buy	117,436 +53,225	+83%	+$625K	0.03%	826
2022 Q4	$736K	Buy	+64,211	New	+$529K	0.02%	1027
2017 Q3	–	Sell	-1,766	Closed	-$17K	–	870
2017 Q2	$17K	Buy	+1,766	New	+$36.1K	﹤0.01%	644
2016 Q4	–	Sell	-1,271	Closed	-$64K	–	1045
2016 Q3	$64K	Buy	+1,271	New	+$52.8K	0.01%	673

Other funds holding MACK

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Boothbay Fund Management's MACK Position: Q3 2023 in Review

Boothbay Fund Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2023, closing a stake of 46,437 shares — an estimated $571K sold.

Boothbay Fund Management first reported a position in MACK in Q3 2016 and held it in 5 quarters. The position peaked at $1.44M in Q1 2023. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2023.

Boothbay Fund Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 46,437 Merrimack Pharmaceuticals, Inc. shares in Q3 2023, an estimated $571K.
Boothbay Fund Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2016 and held it in 5 quarters.
Boothbay Fund Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.44M in Q1 2023.
63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.